When minutes matter: Interleukin-6 between early warning system and high-performance diagnostics

It is 3:17 a.m. in the emergency room.

A 68-year-old patient is admitted with fever, hypotension, and increasing confusion. The clinical picture is nonspecific. Sepsis? Pneumonia? Postoperative complication?

CRP is still normal.

Procalcitonin is pending.

But one value is already beginning to rise—hours before other markers react: interleukin-6 (IL-6).

 

IL-6—a messenger substance with a key function

Interleukin-6 (IL-6) is a proinflammatory cytokine and a central mediator of the immune response. It plays a key role in the regulation of inflammatory processes and in the acute phase response [1,2].

IL-6 is produced by numerous cell types, including monocytes, macrophages, endothelial cells, fibroblasts, keratinocytes, mast cells, T cells, and various tumor cell lines [1,3].

Molecularly, IL-6 is synthesized as a propeptide with 212 amino acids. After cleavage, a mature protein consisting of 184 amino acids with a molecular weight of approximately 21.5–28 kDa is formed, depending on the degree of glycosylation [1].

This structural versatility is reflected in its biological effect: IL-6 is a pleiotropic cytokine with context-dependent effects.

 

How IL-6 works in the body

IL-6 performs several key functions in the immune system:

• Activation of the hepatic acute phase response (e.g., CRP, fibrinogen, ferritin) [2]
• Differentiation of B cells into immunoglobulin-secreting plasma cells [1]
• Activation and modulation of T cells
• Promotion of cytotoxic T cell differentiation in combination with IL-2 [3]
• Involvement in fever, hematopoiesis, and metabolic changes

Classic and trans signaling

IL-6 acts via two signaling pathways:

1. Classical signaling:

Binding to the membrane-bound IL-6 receptor (IL-6R) with subsequent gp130 dimerization and intracellular kinase activation [4].

2. Trans signaling:

Binding to soluble IL-6 receptors (sIL-6R) with subsequent activation of gp130. This mechanism is crucial for the recruitment of lymphocytes to inflamed tissue and for the proinflammatory effect of IL-6 [4,5].

This dual signaling structure explains the physiological and pathological effects of the cytokine.

 

Why IL-6 reacts so quickly

IL-6 is rapidly released in response to infections, trauma, surgical stress, burns, neoplasms, or transplant rejection [6].

A clinically significant advantage:

IL-6 rises within a few hours of inflammatory stimulation—much earlier than CRP [7].

IL-6 is particularly important in neonatology. Guidelines for the diagnosis of neonatal sepsis emphasize the high sensitivity of IL-6 in the early stages of bacterial infections. Elevated levels can be detected 24–48 hours before clinical manifestation [8].

 

IL-6 in emergency and intensive care medicine

In acute medicine, time is a prognostic factor.

Emergency room

IL-6 enables early differentiation between:

• Uncomplicated infection
• Systemic inflammatory response syndrome (SIRS)
• Manifest sepsis

High IL-6 levels correlate with:

• Severity of systemic inflammation
• Risk of shock
• Organ failure [6,9]

Intensive care

In the ICU, IL-6 is primarily used for prognostic purposes:

• Very high values → poorer prognosis in sepsis [9]
• Persistently elevated levels → indication of ongoing hyperinflammation
• Correlation with ARDS severity, duration of ventilation, and mortality [10]
• Predictor of multiple organ failure after polytrauma [11]

After isolated traumatic brain injury, elevated IL-6 levels within the first 48 hours indicate an unfavorable outcome [11].

 

IL-6 compared to CRP and procalcitonin

CRP is an IL-6-dependent acute-phase protein and rises with a delay [2].

Procalcitonin (PCT) has a higher specificity for bacterial infections.

IL-6 is characterized by:

✔ very early increase

✔ high sensitivity to inflammatory dynamics

✖ low specificity

.

Its strength therefore lies in progress assessment and risk stratification, not in isolated diagnosis.

 

Cytokine storm and therapeutic relevance

A cytokine storm is a life-threatening hyperinflammation syndrome with massively elevated cytokine levels. Severe COVID-19 courses have impressively demonstrated the clinical relevance of IL-6 [12].

IL-6 serves here as:

• an early marker of hyperinflammation
• a prognostic parameter
• a therapeutic target

IL-6 receptor antagonists such as tocilizumab are used for selected indications [13].

 

From biology to measurement technology

The clinical relevance of an early marker depends crucially on the analytical quality of the measurement.

IL-6 is predominantly determined using chemiluminescence immunoassay (CLIA). This method offers:

• high analytical sensitivity
• high specificity
• good reproducibility
• short turnaround times [14]

Principle of competitive CLIA

• Antibodies are immobilized on paramagnetic microparticles
• Incubation with patient sample
• Addition of an isoluminol-labeled tracer
• Magnetic separation
• Luminometric detection

The oxidation of isoluminol leads to light emission, which is measured by a photomultiplier. The signal intensity is proportional to the analyte concentration and is quantified using a standard curve [14].

 

IL-6 in the context of consolidated platforms

Modern CLIA platforms such as the Snibe MAGLUMI X series or systems such as the Immu F6 from Medcaptain integrate IL-6 into highly automated workflow structures.

These platforms enable:

• rapid availability of emergency parameters
• parallel determination of routine and special diagnostics
• consolidated device structures
• reproducible calibration
• stable analytical performance

In emergency and intensive care diagnostics in particular, the combination of analytical sensitivity and short turnaround time is crucial for clinical decision-making processes.

 

Clinical bottom line

Interleukin-6 is:

• an early and sensitive marker of systemic inflammation
• a prognostic parameter for sepsis, ARDS, and polytrauma
• an important parameter in neonatology and pediatrics
• a therapeutic target for hyperinflammation

Its greatest clinical value lies in the dynamics of its progression.

 

Back to the emergency room.

3:17 a.m.

The IL-6 level is significantly elevated.

Even before CRP or clinical signs escalate, it allows for early therapeutic decisions. Fluid therapy, anti-infectives, close monitoring.

Sometimes it is not the loudest marker that decides, but the earliest.

And this is exactly where the story of IL-6 begins.